Cara Therapeutics, Inc. (CARA)
After hours:
| Previous close | 0.8052 |
| Open | 0.8000 |
| Bid | 0.7247 x 100 |
| Ask | 0.7707 x 200 |
| Day's range | 0.7500 - 0.8000 |
| 52-week range | 0.5000 - 4.4500 |
| Volume | |
| Avg. volume | 576,322 |
| Market cap | 41.012M |
| Beta (5Y monthly) | 0.73 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -2.2600 |
| Earnings date | 05 Aug 2024 - 09 Aug 2024 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | 5.23 |
ZacksCara Therapeutics (CARA) Reports Q1 Loss, Misses Revenue Estimates
Cara (CARA) delivered earnings and revenue surprises of -47.37% and 5.11%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?
GlobeNewswireCara Therapeutics Reports First Quarter 2024 Financial Results
Topline efficacy and safety results from KOURAGE 1 Part A portion of notalgia paresthetica (NP) pivotal program now expected by the end of 2Q24STAMFORD, Conn., May 13, 2024 (GLOBE NEWSWIRE) -- Cara Therapeutics, Inc. (Nasdaq: CARA), a development-stage biopharmaceutical company leading a new treatment paradigm to improve the lives of patients suffering from pruritus, today announced financial results and operational highlights for the first quarter ended March 31, 2024. “Our notalgia paresthetic
- GlobeNewswire
Cara Therapeutics to Announce First Quarter 2024 Financial Results on May 13, 2024
STAMFORD, Conn., May 06, 2024 (GLOBE NEWSWIRE) -- Cara Therapeutics, Inc. (Nasdaq: CARA), a development-stage biopharmaceutical company leading a new treatment paradigm to improve the lives of patients suffering from pruritus, today announced the Company will report first quarter 2024 financial results on Monday, May 13, 2024, after the U.S. markets close. The press release will be available under “Press Releases” in the Investors section of the Company’s website at www.CaraTherapeutics.com. Abo
